Press coverage about Esperion Therapeutics (NASDAQ:ESPR) has been trending somewhat positive on Saturday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Esperion Therapeutics earned a news impact score of 0.21 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.3951211164314 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
Several research analysts have recently issued reports on ESPR shares. BidaskClub raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Northland Securities reaffirmed a “buy” rating and set a $72.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Bank of America raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price objective for the company in a research report on Friday, January 5th. Stifel Nicolaus reissued a “buy” rating and issued a $70.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Finally, Chardan Capital reissued a “neutral” rating and issued a $75.00 target price (up previously from $20.00) on shares of Esperion Therapeutics in a report on Tuesday, December 5th. Six research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $62.08.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up $3.35 during trading on Friday, hitting $73.26. The stock had a trading volume of 917,587 shares, compared to its average volume of 475,488. Esperion Therapeutics has a fifty-two week low of $10.71 and a fifty-two week high of $74.95. The stock has a market capitalization of $1,831.48, a P/E ratio of -10.66 and a beta of 2.73.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter last year, the firm posted ($0.77) earnings per share. research analysts anticipate that Esperion Therapeutics will post -7.36 earnings per share for the current year.
In other news, Director Nicole Vitullo sold 9,326 shares of Esperion Therapeutics stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now directly owns 2,472 shares of the company’s stock, valued at $133,117.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 32.50% of the company’s stock.
WARNING: “Esperion Therapeutics (NASDAQ:ESPR) Earns Media Sentiment Rating of 0.21” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/esperion-therapeutics-espr-given-daily-news-sentiment-rating-of-0-21.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.